(R)-Zanubrutinib

CAS No. 1691249-44-1

(R)-Zanubrutinib( —— )

Catalog No. M33186 CAS No. 1691249-44-1

(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 78 In Stock
5MG 73 In Stock
10MG 136 In Stock
25MG 226 In Stock
50MG 333 In Stock
100MG 457 In Stock
200MG 635 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (R)-Zanubrutinib
  • Note
    Research use only, not for human use.
  • Brief Description
    (R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
  • Description
    (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1691249-44-1
  • Formula Weight
    471.55
  • Molecular Formula
    C27H29N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 64.25 mg/mL (136.25 mM; Ethanol : < 1 mg/mL (insoluble)
  • SMILES
    NC(=O)c1c2NCC[C@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21.?
molnova catalog
related products
  • ARQ-531

    ARQ-531 (ARQ531) is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, respectively.

  • AVL-292 besylate

    AVL-292 besylate (Spebrutinib, CC-292) is a highly selective, covalent Btk inhibitor with IC50 of <1 nM.

  • Tirabrutinib

    A potent, selective, third-generation irreversible inhibitor of mutant EGFR.